NICE says no to three colorectal cancer drugs
05 September 2011
Mike Ward
Please Login to read the full article.
05 September 2011
Mike Ward
Please Login to read the full article.
RELATED CONTENT
NEWS
- NICE: no evidence to approve Merck Serono's Erbitux, Roche's Avastin and Amgen's Vectibix for second-line mCRC
- NICE scopes Sanofi/Regeneron's Zaltrap for colorectal cancer
- Roche pins Tarceva hope on Cancer Drugs Fund after NICE rejects appeal
- NICE no for Tyverb and Herceptin in breast cancer, Roche considers appeal
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
